Is NCT07037459 recruiting in Yuma, AZ?

Yes, NCT07037459 is currently recruiting participants at its Yuma, AZ location. This heart failure clinical trial is actively enrolling qualified participants.

How do I join the heart failure clinical trial in Yuma?

To join this clinical trial in Yuma, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Yuma clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Heart Failure Clinical Trial in Yuma, AZ

About This Heart Failure Study in Yuma

This study will examine if maridebart cafraglutide as an adjunct to standard of care will lead to a reduction in heart failure (HF) events such as HF hospitalizations and urgent HF visits, cardiovascular (CV) deaths and improvement in HF symptoms in participants with HF with preserved ejection fraction (HFpEF) and HF with mildly reduced ejection fraction (HFmrEF) who are obese. This is a phase 3, global, multicenter, 2-part study with a double-blind period and an open-label extension (OLE). The

Sponsor: Amgen

Who Can Participate

Inclusion Criteria

Age ≥ 18 years at the time of informed consent.

BMI ≥ 30.0 kg/m\^2 at randomization.

HF diagnosed for at least 30 days with New York Heart Association (NYHA) Class II-IV at the time of informed consent.

Managed with HF standard of care therapies.

Left ventricular ejection fraction (LVEF) of \> 40% within 12 months before randomization.

Exclusion Criteria

History of any of the following within 60 days prior to or during screening: Type I (spontaneous) MI, valvular replacement or repair, coronary revascularization, coronary artery bypass graft surgery or other major cardiovascular surgery, stroke.

HF due to: hypertrophic cardiomyopathy, infiltrative cardiomyopathy, active or chronic myocarditis, constrictive pericarditis, cardiac tamponade, arrhythmogenic right ventricular or left ventricular cardiomyopathy/dysplasia, uncorrected primary valvular heart disease, clinically significant congenital heart disease.

Hospitalized with acute decompensated HF at the time of or during the screening period.

Type 1 diabetes mellitus, or any type of diabetes with the exception of T2DM or history of gestational diabetes.

For participants with a prior diagnosis of T2DM (including those diagnosed during screening):

HbA1c \> 10.0% (86 mmol/mol) at screening

Uncontrolled diabetes requiring immediate therapy

History of diabetic ketoacidosis or hyperosmolar state/coma within 12 months before randomization

One or more episodes of severe hypoglycemia within 6 months before randomization and/or history of hypoglycemia unawareness

History or presence of either proliferative diabetic retinopathy, or diabetic maculopathy, or severe non-proliferative diabetic retinopathy; or currently receiving or planning to receive treatment for diabetic retinopathy and/or macular edema.

SBP ≥ 180 mmHg during the screening period, or on three or more blood pressure-lowering drugs with a SBP \> 160 mmHg during the screening period (including day 1 prior to randomization).

History of chronic pancreatitis or acute pancreatitis in the 180 days before screening or during the screening period.

Any personal lifetime history of, or family history(first-degree relative\[s\]) of medullary thyroid carcinoma or MEN-2.

eGFR \< 20 mL/min/1.73 m\^2 (CKD-EPI creatinine (Cr)-cystatin C equation) or receiving dialysis at screening.

Calcitonin ≥ 50 ng/L (pg/mL) at screening.

Acute or chronic hepatitis.

Any of the following psychiatric history:

History of unstable major depressive disorder or other severe psychiatric disorder within 2 years prior to screening or during the screening period

Lifetime history of suicide attempt

History of non-suicidal self-injury within 5 years prior to screening or during the screening period.

History of any other condition that, in the opinion of the investigator, may preclude the participant from following the protocol and completing the trial.

Use of any glucagon-like peptide 1 receptor agonist (GLP-1 RA), glucose-dependent insulinotropic polypeptide (GIP) agonists or antagonists, or amylin analogs within 90 days prior to or during the screening period or planned use during the conduct of the trial.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Yuma?

Yes, this clinical trial (NCT07037459) has an active research site in Yuma, AZ that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Heart Failure Treatment Options in Yuma, AZ

If you're searching for heart failure treatment options in Yuma, AZ, this clinical trial (NCT07037459) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Yuma research site is actively enrolling participants for this phase 3 clinical trial. You'll receive care from experienced heart failure specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all heart failure clinical trials near you to find additional studies recruiting in your area.

Heart Failure Clinical Trial in Yuma, AZ

Expert Care in Yuma

IRB Approved

No-Cost Care

Apply for This Yuma Location

Why Participate?

Simple Process